Loading...
•
Dec 31, 2023
Veru Q1 2024 Earnings Report
Veru's financial results for Q1 2024 were announced and the company's pipeline advancements were highlighted.
Key Takeaways
Veru Inc. reported a decrease in net revenues to $2.1 million from $2.5 million, and an increase in gross profit to $1.2 million from $0.7 million compared to the previous year. The company's cash and cash equivalents totaled $40.6 million. The FDA cleared the IND application for enobosarm in combination with GLP-1 drugs, and the Phase 2b obesity study is expected to begin by April 2024.
FDA cleared the IND application for enobosarm in combination with GLP-1 drugs for weight loss.
Phase 2b obesity study is scheduled to commence by April 2024.
A public offering was completed, yielding net proceeds of $35.2 million.
Cash and cash equivalents reached $40.6 million as of December 31, 2023.
Veru
Veru
Forward Guidance
Veru Inc. is focused on advancing its pipeline, particularly enobosarm for obesity, and sabizabulin for viral-induced ARDS, while managing financial resources and seeking external funding for further development.
Positive Outlook
- Planned Phase 2b trial of enobosarm is expected to commence by April 2024.
- Data from the Phase 2b trial is anticipated to be available by the end of 2024.
- Clinical trial participants are expected to continue into an open-label extension study.
- Enobosarm is expected to meet unmet need for obesity patients by preserving muscle and physical function while augmenting fat loss.
- The company is focused on transforming into a late-stage biopharmaceutical company focused on obesity and oncology.
Challenges Ahead
- Continued clinical development of enobosarm for metastatic breast cancer is subject to sufficient funding.
- Further development of sabizabulin for viral-induced ARDS is contingent upon securing external funding.
- Uncertainties related to market conditions could affect the company's plans.
- The company's expectations regarding the completion, timing, and size of the proposed public offering may not be met.
- There are risks detailed in the company's periodic reports filed with the SEC, including the company's Form 10-K for the year ended September 30, 2023.